Increased glycated albumin and decreased esRAGE concentrations are associated with in-stent restenosis in Chinese diabetic patients

Clin Chim Acta. 2008 Oct;396(1-2):33-7. doi: 10.1016/j.cca.2008.06.019. Epub 2008 Jun 26.

Abstract

Background: We investigated the impact of glycated albumin (GA) and endogenous secretory receptor for advanced glycation end products (esRAGE) and RAGE polymorphisms on occurrence of in-stent restenosis (ISR) in Chinese patients with type 2 diabetes.

Methods: Four hundred nineteen patients with diabetes were divided, based upon the presence or absence of coronary artery disease (CAD) and ISR, into Group I (205 patients without CAD), Group II (128 patients with CAD but without ISR) and Group III (86 patients with ISR). One hundred fifty-two normal subjects were served as controls. Serum concentrations of GA and esRAGE were measured, and RAGE polymorphisms (-374T>A, -429T>C and G82S) were analyzed.

Results: Serum GA concentration was higher and, in contrast, esRAGE concentration was lower in Group III than in the other groups (P<0.05). These two protein concentrations correlated closely with loss index (all P<0.01), and were independent risk factors for ISR in diabetic patients (P=0.01 and P=0.025, respectively). However, there were no differences in the allele and genotype frequencies in the 3 polymorphisms of RAGE gene between groups.

Conclusions: Increased GA and decreased esRAGE concentrations, but not -374T>A, -429T>C and Gly82Ser polymorphisms of RAGE gene, are associated with ISR in Chinese patients with type 2 diabetes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • China / epidemiology
  • Coronary Restenosis / blood*
  • Coronary Restenosis / complications*
  • Coronary Restenosis / epidemiology
  • Diabetes Complications / blood*
  • Diabetes Complications / epidemiology
  • Female
  • Glycated Serum Albumin
  • Glycation End Products, Advanced / blood*
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Risk Factors
  • Serum Albumin / metabolism*
  • Stents

Substances

  • Glycation End Products, Advanced
  • Serum Albumin
  • Glycated Serum Albumin